Prognoza
Średnia cena docelowa analityków wynosi 15,47 € (+343,27%). Mediana wynosi 18,20 € (+421,49%).
| Kupuj |
8 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Nuvation Bio reports strong launch of IBTROZI and positive Safusidenib data
At the Cantor Fitzgerald Healthcare Conference, Nuvation Bio said IBTROZI reached roughly 20% of the theoretical ROS1 market in its first year and uptake in first-line therapy continues to grow. The company holds $700 million in cash and considers itself well positioned financially to fund commercialization and its pipeline. Safusidenib showed a 79% non‑progression rate and a 52% response rate at 3 years, and multiple studies are planned through 2029. Management forecasts a peak sales potential for IBTROZI of $4–5 billion at full market penetration, while warning of development risks and emphasizing disciplined capital deployment. » Więcej na de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib and Cantor-Fitzgerald starts coverage with 12 USD target
The FDA granted safusidenib fast-track status for the treatment of IDH1‑mutated gliomas based on phase 2 data (confirmed objective response rate 51.9%, median progression‑free survival not yet reached, 36‑month PFS 79.1%). The designation enables more intensive interaction with the agency and a possible rolling review, reducing regulatory risk while the phase 3 SIGMA study continues to enroll. Cantor Fitzgerald initiated coverage with an “Overweight” rating and set a price target of 12 USD, with revenue forecasts of roughly 965 million USD for IBTROZI and about 1.9 billion USD for safusidenib. The news pushed the stock higher intraday (rise to 7.02 USD). » Więcej na de.investing.com
Nuvation Bio receives FDA fast-track for safusidenib in IDH1 gliomas
The FDA has granted fast-track designation to safusidenib, an oral investigational candidate from Nuvation Bio for the treatment of IDH1‑mutant gliomas. The decision is based on phase‑2 data (J201) showing a confirmed objective response rate of 51.9% and a 36‑month progression‑free survival of 79.1%; median PFS has not yet been reached. Nuvation is currently recruiting for the registrational phase‑3 SIGMA trial, which will evaluate safusidenib as maintenance therapy versus placebo after standard treatment in IDH1‑mutant astrocytomas with high‑risk features (about 300 patients). Safusidenib is a selective inhibitor of mutant IDH1 designed to penetrate the blood–brain barrier; no new long‑term safety signals have been reported. » Więcej na de.investing.com
Nuvation Bio receives Overweight from JPMorgan after robust second quarter
Nuvation Bio reports a solid second quarter and cash of $661 million. JPMorgan initiated coverage with an "Overweight" rating and a $13 price target, supported by expected first-line uptake. The bank sees additional revenue potential in prevalence-driven gene sequencing and in the pipeline around Safusidenib; the company remains focused on targeted cancer therapies and has a strengthened capital base. » Więcej na finanzen.net
Nuvation Bio reports Q2 revenue growth for IBTROZI and expands safusidenib trials
Nuvation Bio posted Q2 total revenue of $31.7 million with U.S. IBTROZI product sales of $23.2 million, a 25% sequential increase as use shifts toward first-line ROS1 patients. Management highlighted stronger first-line uptake and longer treatment durations, supported by favorable TRUST-I and patient-reported outcomes. The company expanded safusidenib development with a Phase III trial in newly diagnosed Grade 2 IDH1-mutant glioma and a Phase II study for post-vorasidenib patients, citing durable Phase II results. Nuvation ended June with $661 million in cash and securities and raised about $279.1 million via convertible notes, which management says supports operations through profitability and the anticipated safusidenib launch. » Więcej na finance.yahoo.com
Dane finansowe
W ostatnim kwartale Nuvation Bio Inc Ordinary Shares - Class A osiągnęła przychody w wysokości 39,68 mln € i zysk netto w wysokości -36,99 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 39,68 mln | 254,97% |
| Zysk brutto | 29,15 mln | 250,14% |
| Zysk netto | -36,99 mln | 22,19% |
| EBITDA | -31,08 mln | 33,39% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,21 mld € |
Liczba akcji | 352,02 mln |
Maksimum/minimum z 52 tygodni | 8,87 € - 3,43 € |
| Dywidendy | Nie |
Beta | 1,73 |
C/Z (PE Ratio) | -9,58 |
PEG (PEG Ratio) | -0,20 |
C/WK (PB Ratio) | 5,83 |
C/S (PS Ratio) | 6,60 |
Profil spółki
Nuvation Bio Inc., firma biofarmaceutyczna będąca na etapie badań klinicznych, koncentruje się na opracowywaniu kandydatów na leki terapeutyczne w onkologii. Głównym kandydatem na produkt firmy jest NUV-422, mały inhibitor cząsteczkowy kierowany na kinazy zależne od cyklin (CDK)2, CDK4 i CDK6. Firma rozwija również NUV-868, selektywny doustny mały inhibitor cząsteczkowy BET, który epigenetycznie reguluje białka kontrolujące wzrost i różnicowanie guzów; NUV-569, zróżnicowany doustny, mały, selektywny inhibitor kinazy Wee1 odpowiedzialny za naprawę uszkodzeń DNA; NUV-1182, inhibitor receptora adenozynowego; oraz platformę koniugatów lek-lek (DDC), która koncentruje się na połączeniu inhibitora polimerazy poli(ADP-rybozy) (PARP) z przeciwnowotworowymi ładunkami istniejących leków, a także na inhibitorze PARP przeznaczonym do leczenia raka piersi ER+ i raka jajnika. Firma wcześniej funkcjonowała pod nazwą RePharmation Inc. i w kwietniu 2019 roku zmieniła nazwę na Nuvation Bio Inc. Nuvation Bio Inc. została założona w 2018 roku i ma siedzibę główną w Nowym Jorku (Nowy Jork).
| Nazwa | Nuvation Bio Inc Ordinary Shares - Class A |
| CEO | David T. Hung |
| Siedziba | New York City,
ny Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 26.08.2020 |
| Pracownicy | 310 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NYSE | NUVB |